Exchange Traded Concepts’s BridgeBio Pharma BBIO Stock Holding History

Exchange Traded Concepts’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-222	Closed	-$6.09K	–	1275
2024 Q4	$6.09K	Buy	+222	New	+$5.74K	﹤0.01%	1357
2024 Q2	–	Sell	-103	Closed	-$3.19K	–	1217
2024 Q1	$3.19K	Buy	+103	New	+$3.5K	﹤0.01%	1218
2022 Q1	–	Sell	-19,733	Closed	-$329K	–	1211
2021 Q4	$329K	Buy	+19,733	New	+$835K	0.01%	738
2021 Q2	–	Sell	-134	Closed	-$8K	–	1108
2021 Q1	$8K	Buy	+134	New	+$8.77K	﹤0.01%	998

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Exchange Traded Concepts's BBIO Position: Q1 2025 in Review

Exchange Traded Concepts sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 222 shares — an estimated $6.09K sold.

Exchange Traded Concepts first reported a position in BBIO in Q1 2021 and held it in 4 quarters. The position peaked at $329K in Q4 2021. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

Exchange Traded Concepts reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
Exchange Traded Concepts sold 222 BridgeBio Pharma shares in Q1 2025, an estimated $6.09K.
Exchange Traded Concepts first reported a position in BridgeBio Pharma in Q1 2021 and held it in 4 quarters.
Exchange Traded Concepts's BridgeBio Pharma position peaked at $329K in Q4 2021.
304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on Exchange Traded Concepts's 13F filing for Q1 2025, filed 17 Apr 2025.